Last updated: September 24, 2026
ALA-CORT is a prescription topical hydrocortisone product used for corticosteroid-responsive dermatoses. Its commercial outlook is shaped by generic competition, low ingredient costs, widespread over-the-counter hydrocortisone availability, and limited product differentiation. No public source identifies standalone ALA-CORT revenue, operating profit, or a distinct product-level forecast. The economic profile is therefore best assessed through market structure, pricing pressure, regulatory status, and the financial position of its manufacturer, Taro Pharmaceuticals.
What is ALA-CORT and who manufactures it?
ALA-CORT is a topical cream containing hydrocortisone 1%. The product is indicated for temporary relief and treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. The label identifies Taro Pharmaceuticals U.S.A., Inc. as the manufacturer or distributor for the U.S. product.[1]
| Attribute |
ALA-CORT profile |
| Active ingredient |
Hydrocortisone |
| Strength |
1% |
| Dosage form |
Topical cream |
| Route |
Dermatologic, external use |
| Therapeutic class |
Topical corticosteroid |
| U.S. regulatory status |
Prescription product under product labeling |
| Primary indications |
Corticosteroid-responsive dermatoses |
| Manufacturer associated with U.S. labeling |
Taro Pharmaceuticals U.S.A., Inc. |
| Primary commercial substitutes |
Generic hydrocortisone cream, OTC hydrocortisone products, branded dermatology corticosteroids |
Hydrocortisone is a long-established corticosteroid with broad clinical use. ALA-CORT does not depend on a novel active pharmaceutical ingredient, biologic platform, delivery device, or specialized administration technology.
How large is the ALA-CORT market?
The addressable market is the U.S. topical hydrocortisone market rather than a standalone ALA-CORT market. Hydrocortisone 1% products are available from multiple generic manufacturers and are also sold through over-the-counter channels under the FDA’s topical corticosteroid framework.[2]
The market has several structural characteristics:
- The active ingredient is mature and widely available.
- Manufacturing requirements for a conventional cream are established.
- Retail and private-label products compete directly with prescription products.
- Pharmacists and payers can substitute generic hydrocortisone products.
- Patients can often obtain comparable-strength products without a prescription.
These factors reduce the price premium available to a prescription brand. ALA-CORT may retain demand where prescribers prefer a prescription product, insurers require a prescription product for reimbursement, or pharmacies stock a particular manufacturer’s product. Those advantages are limited because the underlying molecule and dosage form are widely commoditized.
What drives demand for ALA-CORT?
Demand is linked to common inflammatory and pruritic skin conditions, including eczema-like eruptions, dermatitis, allergic reactions, and other steroid-responsive conditions. Prescribing volume is influenced by primary-care and dermatology visits, seasonal skin irritation, formulary status, pharmacy availability, and substitution rules.
Clinical demand is relatively stable but does not create strong long-term brand loyalty. Patients and prescribers generally have access to alternative topical corticosteroids, including products with different potencies, formulations, or active ingredients.
What is the financial trajectory for ALA-CORT?
No publicly reported financial filing separately discloses ALA-CORT revenue, gross margin, prescription volume, or cash flow. Taro’s public reporting aggregates products across therapeutic categories and geographic markets rather than reporting individual mature topical products.[3]
The likely financial trajectory is that of a mature, low-growth generic or legacy prescription product:
| Financial factor |
Expected effect on ALA-CORT |
| Unit demand |
Stable to modestly declining |
| Net price |
Persistent downward pressure |
| Gross margin |
Dependent on manufacturing scale and contract pricing |
| Marketing expense |
Likely limited relative to branded dermatology products |
| Regulatory cost |
Low but recurring |
| Product-level growth potential |
Limited |
| Revenue concentration risk |
Low if the product is a small part of the portfolio |
| Strategic value |
Portfolio breadth, channel access, and manufacturing utilization |
The main financial risk is price erosion rather than abrupt loss of exclusivity. ALA-CORT’s commercial value is likely tied to efficient production, pharmacy distribution, and portfolio economics. A product with low unit cost can remain commercially useful even at low prices if it has repeat demand and minimal promotional expense.
Taro’s overall results cannot be used as a direct proxy for ALA-CORT performance. The company sells a broad portfolio of generic and specialty pharmaceutical products, and product-level contribution is not separately identified in its public reporting.[3]
When does ALA-CORT lose exclusivity?
ALA-CORT does not have a commercially meaningful exclusivity position based on the age of hydrocortisone, the availability of equivalent hydrocortisone products, and the absence of a differentiated delivery platform.
Hydrocortisone has been used clinically for decades. Any original compound patent has long expired. The relevant commercial question is not the expiration of a historic hydrocortisone patent, but whether any current formulation, method-of-use, or regulatory exclusivity restricts competing products.
| Exclusivity category |
ALA-CORT assessment |
| Active-ingredient patent |
Expired or commercially irrelevant |
| Core composition patent |
No material blocking position identified |
| Formulation patent |
No publicly established ALA-CORT-specific barrier identified |
| Method-of-use patent |
No material exclusivity identified |
| Orphan-drug exclusivity |
Not applicable |
| New chemical entity exclusivity |
Not applicable |
| Pediatric exclusivity |
No product-specific period identified |
| Market exclusivity |
Functionally absent in a mature generic market |
What is the Orange Book status of ALA-CORT?
The commercial significance of Orange Book protection for ALA-CORT is limited. Orange Book-listed patents are most important for approved drug products supported by patents that can delay or restrict ANDA approval. A mature topical hydrocortisone product generally does not have the patent profile associated with a newly approved branded medicine.[4]
The relevant regulatory issues are:
- Whether the specific ALA-CORT product is listed as a reference or prescription product.
- Whether an approved generic can demonstrate pharmaceutical equivalence.
- Whether any patent information is listed for the specific product.
- Whether a generic applicant can file an ANDA without a Paragraph IV challenge.
- Whether state substitution and payer policies favor the lowest-cost equivalent.
A patent listing, if present for a specific product, would not necessarily create durable economic protection. Topical hydrocortisone competitors can also enter through alternative approved products or OTC pathways, depending on strength, labeling, formulation, and regulatory status.
What formulation patents protect ALA-CORT?
No material ALA-CORT formulation patent barrier is evident from the product’s conventional hydrocortisone cream profile. The product uses a standard semisolid topical dosage form rather than a proprietary transdermal system, nanoformulation, metered-dose device, or controlled-release platform.
Potential technical differences between topical hydrocortisone products can include:
- Cream vehicle composition.
- Preservative system.
- Emulsion characteristics.
- Spreadability and skin feel.
- Stability profile.
- Packaging configuration.
- Manufacturing process controls.
Those differences may support product quality or manufacturing know-how, but they do not automatically create enforceable market exclusivity. A competitor can develop an equivalent cream through its own formulation and demonstrate the required pharmaceutical equivalence or regulatory comparability.
Are there Paragraph IV challenges to ALA-CORT?
No publicly identified Paragraph IV litigation specific to ALA-CORT establishes a current market threat or creates a major commercial event. This is consistent with the product’s mature market position.
Paragraph IV litigation is more common when a branded product has active Orange Book patents and substantial expected revenue. A conventional hydrocortisone 1% cream has limited litigation value because:
- Competing hydrocortisone products are already widely available.
- The active ingredient is old.
- Market prices are low.
- Potential damages are unlikely to justify extensive litigation.
- Alternative products can often satisfy the same clinical demand.
The more relevant competitive threat is routine generic substitution and retail-channel competition, not a single high-profile patent challenge.
What litigation affects ALA-CORT?
No material ALA-CORT-specific patent litigation is identified in the available public product and corporate materials. There is also no evident settlement agreement that would delay generic entry or establish a market-sharing arrangement involving ALA-CORT.
The absence of high-value litigation is commercially important. It indicates that the product’s market position depends more on supply reliability, manufacturing economics, distribution, and formulary access than on enforcement of exclusionary rights.
Which companies challenge ALA-CORT commercially?
ALA-CORT competes with several groups rather than one direct rival.
Generic hydrocortisone manufacturers
Generic pharmaceutical companies can sell hydrocortisone creams, ointments, lotions, and other topical preparations. Competition occurs at the pharmacy and wholesaler level, where price, inventory, reimbursement, and supplier reliability drive product selection.
OTC manufacturers
OTC brands and private-label retailers sell hydrocortisone 0.5% and 1% products under the FDA’s nonprescription framework.[2] These products are major substitutes because consumers can purchase them without a physician visit.
Branded dermatology products
Higher-potency corticosteroids and nonsteroidal dermatology products compete for prescriptions where clinicians need stronger efficacy, a different vehicle, or a steroid-sparing option. These products do not always compete directly on price but can reduce the number of prescriptions written for low-potency hydrocortisone.
Pharmacy and retailer private labels
Private-label hydrocortisone products place additional pressure on retail pricing. Their low marketing costs and broad distribution can make them more attractive to patients and payers than a prescription-branded product.
How does ALA-CORT compare with other topical corticosteroids?
ALA-CORT is positioned at the low-potency end of topical corticosteroid therapy.
| Product category |
Relative potency |
Typical commercial position |
Competitive relationship |
| Hydrocortisone 0.5% or 1% |
Low |
OTC and generic |
Direct substitute |
| ALA-CORT hydrocortisone 1% |
Low |
Prescription topical cream |
Direct substitute |
| Desonide products |
Low |
Prescription dermatology |
Substitutes where a different molecule is preferred |
| Triamcinolone acetonide |
Medium |
Generic prescription |
Competes when greater potency is needed |
| Betamethasone products |
Medium to high |
Generic prescription |
Competes for more severe disease |
| Nonsteroidal topical products |
Variable |
Branded or specialty |
Alternative for steroid-sparing treatment |
ALA-CORT’s low potency supports use in mild disease and on sensitive areas, but it also limits pricing power. Products with stronger clinical differentiation may command higher reimbursement or physician preference.
What manufacturing and intellectual-property barriers exist?
Manufacturing barriers are modest but not zero. A topical cream must meet requirements for identity, strength, microbial quality, stability, uniformity, packaging compatibility, and production consistency. The manufacturer also needs validated processes for the cream base and active-ingredient dispersion.
These requirements can create operational barriers for inexperienced entrants. They do not create a strong legal moat when multiple companies already manufacture equivalent hydrocortisone products.
The most relevant barriers are:
- FDA-compliant topical manufacturing capacity.
- Access to hydrocortisone active ingredient.
- Stable supply of excipients and packaging.
- Demonstrated product quality.
- Wholesale and pharmacy distribution.
- Contract pricing and reimbursement access.
Trade secrets may protect process details, but trade-secret protection does not prevent independent development of a competing product.
What licensing deals involve ALA-CORT?
No material public licensing transaction specifically involving ALA-CORT has been identified. The product does not appear to depend on a publicly disclosed co-development agreement, university license, platform technology license, or specialty distribution partnership.
Any manufacturing, distribution, or supply arrangements may be embedded in private commercial contracts and would not necessarily appear in public filings. ALA-CORT’s economics therefore appear to depend primarily on internal portfolio management and established distribution rather than licensing income.
What generic launch scenarios exist for ALA-CORT?
Because equivalent hydrocortisone products already compete in the market, the most likely scenarios are:
| Scenario |
Market effect |
Financial effect |
| Continued multi-source supply |
Stable low-price demand |
Gradual margin pressure |
| Manufacturer withdrawal |
Temporary supply opportunity for remaining suppliers |
Possible short-term price improvement |
| New low-cost entrant |
More pharmacy substitution |
Lower net price and share |
| Retail channel expansion |
Greater OTC substitution |
Prescription volume erosion |
| Supply disruption |
Temporary inventory shortages |
Short-term volume shift, higher acquisition costs |
| Formulation differentiation |
Limited niche demand |
Modest pricing benefit if clinically meaningful |
The strongest near-term commercial opportunity would arise from a competitor or supplier exit, not from patent exclusivity. Any such benefit would likely be temporary because other hydrocortisone manufacturers can expand production or retailers can shift to private-label alternatives.
What is the biosimilar risk for ALA-CORT?
Biosimilar risk is not relevant because ALA-CORT is a small-molecule topical corticosteroid, not a biologic. The relevant regulatory competition comes from generic drug products and OTC alternatives, not biosimilar products.
This distinction matters because generic entry can occur through the ANDA pathway, while biosimilar products follow the biologics framework under the Public Health Service Act. ALA-CORT has no biologic manufacturing or interchangeability issue.[5]
What is the geographic coverage of ALA-CORT?
The strongest identifiable commercial connection is to the U.S. market through Taro Pharmaceuticals U.S.A. and U.S. product labeling. The brand’s geographic reach outside the United States is not established by the cited materials.
Hydrocortisone itself has broad global availability, but that does not mean the ALA-CORT brand has equivalent international distribution. Outside the United States, products may be sold under different brand names, local manufacturers, or generic labels.
Key Takeaways
- ALA-CORT is a prescription hydrocortisone 1% topical cream associated with Taro Pharmaceuticals.
- Its market is mature, price-sensitive, and exposed to both generic and OTC competition.
- No standalone ALA-CORT revenue or profit data is publicly disclosed.
- The product has no evident commercially meaningful active-ingredient exclusivity.
- No material ALA-CORT-specific formulation patent, Paragraph IV litigation, or settlement barrier is identified.
- Financial performance is likely driven by manufacturing efficiency, distribution, supply reliability, and portfolio contribution.
- Generic substitution and OTC availability create more risk than patent expiration.
- Biosimilar competition does not apply.
- The most probable trajectory is stable or declining unit economics, with limited pricing power and modest strategic value as a portfolio product.
FAQs About ALA-CORT Market and Financial Outlook
Is ALA-CORT the same as over-the-counter hydrocortisone?
ALA-CORT contains hydrocortisone 1%, the same active ingredient and strength found in many OTC products. Prescription status, labeling, packaging, inactive ingredients, and reimbursement treatment may differ.
Can a generic company launch a product equivalent to ALA-CORT?
Yes. A generic manufacturer can compete with hydrocortisone topical products through the applicable FDA approval pathway, subject to formulation, quality, labeling, and equivalence requirements.
Does ALA-CORT have patent protection?
No material patent-based market barrier is evident from its mature hydrocortisone composition and conventional cream formulation. Any product-specific patent listing would need to be evaluated against current FDA records and its legal status.
Is ALA-CORT a high-revenue pharmaceutical product?
There is no public product-level revenue disclosure supporting that conclusion. Its market characteristics indicate a mature, low-price product rather than a high-growth branded asset.
Could ALA-CORT benefit from a competitor shortage?
Yes. A supply disruption or manufacturer withdrawal could temporarily shift volume to available suppliers. The effect would likely be limited by the number of alternative hydrocortisone products and OTC substitutes.
References
- National Library of Medicine. (n.d.). Ala-Cort hydrocortisone cream 1%: Drug label information. DailyMed.
- U.S. Food and Drug Administration. (2022). Over-the-counter monograph M017: Topical corticosteroids. FDA.
- Taro Pharmaceutical Industries Ltd. (2023). Annual report and financial statements.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
- U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable biosimilar products. FDA.
